Hyphens Pharma International eyes Catalist IPO

It lodged a preliminary offer document in the SGX.

Hyphens Pharma International is eyeing an initial public offering (IPO) in Singapore and a listing in the Singapore Exchange (SGX) Catalist board. It lodged a preliminary offer document and announced DBS Bank as its sponsor, underwriter, and placement agent.

Hyphens Pharma is a speciality pharmaceutical and consumer healthcare group with a direct presence in five ASEAN countries, namely, Singapore, Vietnam, Malaysia, Indonesia, and the Philippines.

It sells speciality pharmaceuticals, a proprietary range of dermatological products and health supplement products through Hyphens and Ocean Health Singapore, and medical hypermart and digital supplies.

The proceeds of the IPO will go to business expansion, construction of an integrated facility, and other corporate services.

Its subsidiary, Hyphens Singapore, has previously paid dividends of approximately $1m and $7m for 2016 and 2017 respectively.

It has its regional headquarters in Singapore, where most of its operations are based.